Literature DB >> 11144545

Tuberculosis 2000-2010: control, but not elimination.

C Dye1.   

Abstract

The main task of global tuberculosis (TB) control over the next decade is to dramatically reduce TB deaths, the average duration of illness, and incidence--in that order. The best possible application of chemotherapy has the potential to cut the TB burden by more than 50% in 10 years. Mass screening for active TB has not generally been recommended, but the costs and benefits of targeted active case finding deserve further investigation. Among potential new tools for TB control, the biggest prize would be a high-efficacy vaccine that can produce long-lasting immunity. Now that good control programmes are becoming more widespread, new methods and indicators are needed to evaluate epidemiological impact. Even if morbidity and mortality are significantly reduced before 2010, tuberculosis infection will persist for much longer, acting as a sensitive indicator of public health, and as a marker of the quality of health services.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144545

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  16 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa.

Authors:  D Guwatudde; S M Debanne; M Diaz; C King; C C Whalen
Journal:  Prev Med       Date:  2004-11       Impact factor: 4.018

3.  Factors associated with tuberculosis cases in Semarang District, Indonesia: case-control study performed in the area where case detection rate was extremely low.

Authors:  Sri Ratna Rahayu; Hironobu Katsuyama; Masashi Demura; Midori Katsuyama; Yoko Ota; Hideji Tanii; Tomomi Higashi; Ngakan Putu Djaja Semadi; Kiyofumi Saijoh
Journal:  Environ Health Prev Med       Date:  2015-04-16       Impact factor: 3.674

Review 4.  Health and economic benefits of an accelerated program of research to combat global infectious diseases.

Authors: 
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

5.  Transmissibility of tuberculosis among school contacts: an outbreak investigation in a boarding middle school, China.

Authors:  Mai-Juan Ma; Yang Yang; Hai-Bin Wang; Yi-Fan Zhu; Li-Qun Fang; Xiao-Ping An; Kang-Lin Wan; Christopher C Whalen; Xiao-Xian Yang; Michael Lauzardo; Zhi-Yi Zhang; Jin-Feng Cao; Yi-Gang Tong; Er-Hei Dai; Wu-Chun Cao
Journal:  Infect Genet Evol       Date:  2015-03-07       Impact factor: 3.342

Review 6.  Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Authors:  Kerstin A Wolff; Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

7.  Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis.

Authors:  Jingyu Mu; Mangalakumari Jeyanathan; Cherrie-Lee Small; Xizhong Zhang; Elizabeth Roediger; Xueya Feng; Duncan Chong; Jack Gauldie; Zhou Xing
Journal:  Mol Ther       Date:  2009-03-24       Impact factor: 11.454

Review 8.  To control and beyond: moving towards eliminating the global tuberculosis threat.

Authors:  Timothy F Brewer; S Jody Heymann
Journal:  J Epidemiol Community Health       Date:  2004-10       Impact factor: 3.710

9.  The importance of animal models in tuberculosis vaccine development.

Authors:  Armando Acosta; Mohd Nor Norazmi; Rogelio Hernandez-Pando; Nadine Alvarez; Reinier Borrero; Juan F Infante; Maria E Sarmiento
Journal:  Malays J Med Sci       Date:  2011-10

10.  Diagnostic work-up and loss of tuberculosis suspects in Jogjakarta, Indonesia.

Authors:  Riris Andono Ahmad; Francine Matthys; Bintari Dwihardiani; Ning Rintiswati; Sake J de Vlas; Yodi Mahendradhata; Patrick van der Stuyft
Journal:  BMC Public Health       Date:  2012-02-15       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.